November 18, 2016 - By Dolores Ford · 0 Comments
Alliqua Inc (NASDAQ:ALQA) institutional sentiment decreased to 0.75 in 2016 Q2. Its down -0.25, from 1 in 2016Q1. The ratio turned negative, as 11 active investment managers increased or started new positions, while 11 decreased and sold positions in Alliqua Inc. The active investment managers in our partner’s database now hold: 8.86 million shares, down from 10.42 million shares in 2016Q1. Also, the number of active investment managers holding Alliqua Inc in their top 10 positions was flat from 0 to 0 for the same number . Sold All: 4 Reduced: 7 Increased: 11 New Position: 0.
Alliqua BioMedical, Inc. is a provider of advanced wound care solutions. The company has a market cap of $25.05 million. The Company’s businesses include advanced wound care and contract manufacturing. It currently has negative earnings. The Firm operates through its subsidiaries, such as AquaMed Technologies, Inc. and Choice Therapeutics, Inc.
The stock increased 8.56% or $0.06 on November 17, hitting $0.76. Alliqua Biomedical Inc (NASDAQ:ALQA) has risen 5.56% since April 18, 2016 and is uptrending. It has outperformed by 1.13% the S&P500.
According to Zacks Investment Research, “Alliqua, Inc. is a biomedical company. The company focused on the development, manufacturing and distribution of proprietary transdermal wound care and drug delivery technologies. Its technology platform produces hydrogels, a 3-dimensional cross-linked network of water soluble polymers. The company’s product includes SilverSeal(R) a hydrogel wound dressing with silver coated fibers and Hydress(R) an over-the-counter hydrogel wound dressing. It serves the healthcare industry including wound healing, medical diagnostics and cosmeceuticals. Alliqua, Inc. is headquartered in Langhorne, Pennsylvania.”
Pura Vida Investments Llc holds 0.28% of its portfolio in Alliqua Biomedical Inc for 583,026 shares. Suffolk Capital Management Llc owns 1.21 million shares or 0.17% of their US portfolio. Moreover, Perceptive Advisors Llc has 0.15% invested in the company for 1.92 million shares. The New Jersey-based Sabby Management Llc has invested 0.09% in the stock. Tekla Capital Management Llc, a Massachusetts-based fund reported 1.65 million shares.#img1#
Ratings analysis reveals 100% of Alliqua Biomedical’s analysts are positive. Out of 3 Wall Street analysts rating Alliqua Biomedical, 3 give it “Buy”, 0 “Sell” rating, while 0 recommend “Hold”. The lowest target is $2.25 while the high is $10.0. The stock’s average target of $2.58 is 239.47% above today’s ($0.76) share price. ALQA was included in 8 notes of analysts from August 19, 2015. RBC Capital Markets maintained the shares of ALQA in a report on Friday, November 6 with “Outperform” rating. The company was maintained on Wednesday, February 24 by Chardan Capital Markets. The firm has “Buy” rating given on Wednesday, August 10 by H.C. Wainwright. The stock has “Buy” rating given by Chardan Capital Markets on Friday, November 6. The company was downgraded on Wednesday, August 19 by Zacks. As per Wednesday, February 24, the company rating was maintained by RBC Capital Markets. The stock of Alliqua Biomedical Inc (NASDAQ:ALQA) earned “Buy” rating by H.C. Wainwright on Monday, November 2.
Alliqua BioMedical, Inc., incorporated on April 15, 2014, is a well-known provider of wound care solutions. The Firm operates in commercial wound care segment, which consists of approximately five product categories, such as Wound Bed Preparation & Stimulation; Human Biologics; Antimicrobial Protection; Exudate Management, and Contract Manufacturing. The Firm has a suite of wound care solutions that enable surgeons, clinicians and wound care practitioners to address the challenges in chronic and acute wounds. The Firm has built its portfolio through its hydrogel technology platform, targeted acquisitions, and through licensing and distribution agreements. The Company’s contract manufacturing business provides custom hydrogels to the original equipment maker (OEM) market.
More notable recent Alliqua Biomedical Inc (NASDAQ:ALQA) news were published by: Globenewswire.com which released: “Alliqua BioMedical, Inc. Announces Expansion of Medicare Reimbursement …” on October 10, 2016, also Globenewswire.com with their article: “Alliqua BioMedical, Inc. Announces Preliminary Second Quarter of Fiscal Year …” published on July 07, 2016, Globenewswire.com published: “Alliqua Biomedical Announces Partnership With Human Longevity Inc., Under …” on January 28, 2016. More interesting news about Alliqua Biomedical Inc (NASDAQ:ALQA) were released by: Globenewswire.com and their article: “Alliqua BioMedical, Inc. Announces Closing of Celleration, Inc. Acquisition” published on June 01, 2015 as well as Globenewswire.com‘s news article titled: “Alliqua BioMedical, Inc. Appoints Nino Pionati as Chief Strategy and Marketing …” with publication date: June 03, 2015.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Dolores Ford